NCT02420730View on ClinicalTrials.gov

Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Healthy VolunteersDry Eye Syndromes
Interventions
DRUG

AGN-232411

AGN-232411 topical ophthalmic solution

DRUG

AGN-232411 Vehicle

Vehicle for AGN-232411 topical ophthalmic solution.

Trial Locations (3)

90640

Montebello Medical Center, Inc., Montebello

90701

Sall Research Center, Artesia

91204

Lugene Eye Institute, Glendale

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT02420730 - Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye | Biotech Hunter | Biotech Hunter